Pharmamarketeer

Amgen gets EMA committee positive opinion to expand use of Blincyto in patients with minimal residual disease-positive B-cell precursor ALL

Amgen announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion to expand the current indication for Blincyto

Medhc-fases-banner
Advertentie(s)